Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Haemning af proteinet PCSK9 er en lovende behandling af hyperkolesterolaemi og forebyggelse af hjerte-kar-sygdom
Engelsk titel: Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease Läs online Författare: Krogh Christiansen, Morten ; Kjaerulf Jensen, Henrik Språk: Dan Antal referenser: 25 Dokumenttyp: Översikt UI-nummer: 16037123

Tidskrift

Ugeskrift for Laeger 2015;177(26)2509-12 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Recent research in genetics has revealed that PCSK9 - which codes for proprotein convertase subtilisin/kexin type 9 (PCSK9) - plays a major role in cholesterol regulatory pathways. Normal genetic variations in PCSK9 have a great impact on low-density lipoprotein cholesterol levels and hence the risk of cardio-vascular disease. This has led to huge efforts in inhibiting PCSK9. Recent clinical phase II trials with monoclonal antibodies against PCSK9 have shown great results for lowering low-density lipoprotein cholesterol levels making the inhibition of PCSK9 a promising target in the prevention of cardiovascular disease.